Showing 5331-5340 of 5689 results for "".
- EyePoint Pharmaceuticals Presents Positive Yutiq 36-Month Follow-Up Phase 3 Data at ARVOhttps://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-yutiq-36-month-follow-up-phase-3-data-at-2019-arvo-annual-meeting/2476523/EyePoint Pharmaceuticals announced the presentation of 36-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18-mg micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The data
- Verseon Presents Oral Drug Candidate for Diabetic Eye Diseasehttps://modernod.com/news/verseon-presents-oral-drug-candidate-for-diabetic-eye-disease/2476516/Verseon presented promising preclinical efficacy data for the first development candidate for clinical trials in their diabetic eye disease program at this week’s ARVO 2019 annual meeting in Vancouver. This new drug candidate for oral dosing could lead to the first real alternative to eye injecti
- Sight Sciences Announces Launches of TearCare and the Enhanced OMNI Systemhttps://modernod.com/news/sight-sciences-announces-official-launches-of-tearcare-and-the-enhanced-next-generation-omni-system/2476517/Sight Sciences announced the official commercial launch of TearCare and the introduction of an aesthetically and ergonomically enhanced OMNI Surgical System, which was initially launched in February 2018. The rollout of the new devices will include product dem
- ReNeuron Announces Presentation of Updated Efficacy and Safety Data from Retinitis Pigmentosa Studyhttps://modernod.com/news/reneuron-announces-presentation-of-updated-efficacy-and-safety-data-from-retinitis-pigmentosa-study/2476502/ReNeuron Group announced updated positive preliminary results in the company’s ongoing phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2a part of the trial have demonstr
- Zeiss Launches First Dual-Speed Swept-Source OCT/OCTA at ARVOhttps://modernod.com/news/zeiss-launches-first-dual-speed-swept-source-oct-octa-at-arvo/2476503/Zeiss launched the PLEX Elite 2.0, the first dual-speed swept-source OCT/OCTA that will scan at 200kHz, in addition to 100kHz, providing doctors a more detailed view into the retina. Varying speeds can be applied to different disease states in the eye and expand re
- Presbia Abandons Flexivue Microlens, Lays Off All But 3https://modernod.com/news/presbia-abandons-flexivue-microlens-lays-off-all-but-3/2476501/Presbia said it spiked its Flexivue microlens development program in the face of FDA headwinds, laying off all but three of its employees as it seeks investors to bail it out, according to a Mass Device report. Earlier this month, the Irvine, Calif.-based company
- Aerie Pharmaceuticals Announces Acceptance of Its IND Application for Sustained-Release Implant for Retinal Diseaseshttps://modernod.com/news/aerie-pharmaceuticals-announces-acceptance-of-its-ind-application-for-sustained-release-implant-for-retinal-diseases/2476498/Aerie Pharmaceuticals announced that the FDA has reviewed the investigational new drug (IND) application for AR-13503, a novel multi-kinase (Rho kinase/Protein kinase C (ROCK/PKC)) inhibitor sustained-release implant, and it is now in effect, allowing Aerie to initiate human studies in the treat
- Oxurion Announces Full Enrollment in its Phase 1 Trial Evaluating the Safety of its Plasma Kallikrein Inhibitor THR-149 for Treatment of DMEhttps://modernod.com/news/oxurion-announces-full-enrollment-in-its-phase-1-trial-evaluating-the-safety-of-its-plasma-kallikrein-inhibitor-thr-149-for-treatment-of-dme/2476492/Oxurion NV announced that it has completed enrollment of its phase 1 study of THR-149, a novel plasma kallikrein (PKal) inhibitor for the treatment of diabetic macular edema (DME). A total of 15 patients have been recruited. The study enrolled faster than anticipated and initial data will be rele
- ProtoKinetix AAGP in Phase 3 Retinal Replacement Programhttps://modernod.com/news/protokinetix-aagp-in-phase-3-retinal-replacement-program/2476493/ProtoKinetix updated its stockholders regarding phase 3 of testing using AAGP in retinal cell replacement therapy at the University of British Columbia. The study is now using 2 animal models and a significantly larger number of animals in both control and AAGP treated groups for a longer
- First Clinical Program Initiated Using Nanoparticles to Treat Retinitis Pigmentosahttps://modernod.com/news/first-clinical-program-initiated-using-nanoparticles-to-treat-retinitis-pigmentosa/2476490/2Ctech announced the initiation of the first-known clinical program to demonstrate the effectiveness and safety of Quantum Dots (QDs) to achieve photovoltaic stimulation of the neural retina for preservation or enhancement of vision in patients with retinal degenerative diseases and, in particula